PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP.
Ceska
Richard
R
Stulc
Tomas
T
Zima
Tomas
T
Malbohan
Ivan
I
Fialova
Lenka
L
D000069059:Atorvastatin; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis / Q000187:drug effects*; D003327:Coronary Disease / Q000097:blood; D011345:Fenofibrate / Q000494:pharmacology; D006538:Heptanoic Acids / Q000494:pharmacology; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D011266:Pregnancy-Associated Plasma Protein-A / Q000032:analysis / Q000187:drug effects*; D011758:Pyrroles / Q000494:pharmacology
D015415:Biomarkers; D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D011758:Pyrroles; D002097:C-Reactive Protein; D000069059:Atorvastatin; D011266:Pregnancy-Associated Plasma Protein-A; D011345:Fenofibrate